Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

30 Jun, 2021 | 10:11h | UTC

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta – The Conversation

Related: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv

 

M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

30 Jun, 2021 | 10:08h | UTC

SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis – EClinicalMedicine

 

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

29 Jun, 2021 | 10:09h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases

 

Commentary on Twitter

 

SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.

29 Jun, 2021 | 10:03h | UTC

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature

Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical

Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.

 

Commentary on Twitter (thread – click for more)

 

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

29 Jun, 2021 | 10:07h | UTC

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

 

[Preprint] 3rd AstraZeneca shot gives strong immunity.

29 Jun, 2021 | 10:01h | UTC

Study: 3rd AstraZeneca shot gives strong immunity – Reuters

Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet

 

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

29 Jun, 2021 | 10:00h | UTC

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases

Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

 

EBM Analysis | Does tranexamic acid work for everything? For anything?

29 Jun, 2021 | 09:53h | UTC

Does TXA work for everything? For anything? – First10EM

 

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

28 Jun, 2021 | 10:01h | UTC

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet

Commentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND

 

Commentary on Twitter (thread – click for more)

 

RCT: Similar outcomes with mycophenolate mofetil vs. azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression.

29 Jun, 2021 | 09:50h | UTC

Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial – PLOS One

 

Perspective | Is one vaccine dose enough if you’ve had COVID? What the science says.

28 Jun, 2021 | 09:52h | UTC

Is one vaccine dose enough if you’ve had COVID? What the science says – Nature

Related: Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

 

Commentary on Twitter

 

IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.

28 Jun, 2021 | 09:51h | UTC

Co-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America

Related: Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.

 

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

28 Jun, 2021 | 09:46h | UTC

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet

 

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department.

28 Jun, 2021 | 09:43h | UTC

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department – Annals of Emergency Medicine

 

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.

28 Jun, 2021 | 09:45h | UTC

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D – MedPage Today (free registration required)

 

No evidence yet to suggest Covid vaccine booster is needed, CDC group says.

25 Jun, 2021 | 10:29h | UTC

No evidence yet to suggest Covid vaccine booster is needed, CDC group says – NBC News

Related opinion: 7 Reasons Why We Should Not Need Boosters for COVID-19 – by Monica Ghandi, MD

 

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

25 Jun, 2021 | 10:24h | UTC

The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better – The Atlantic

Related: (Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

 

Commentary on Twitter

 

RCT: Doxycycline for 7 days superior to single-dose azithromycin for the treatment of rectal chlamydia infection.

25 Jun, 2021 | 10:19h | UTC

Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Doxycycline Superior to Azithromycin for Asymptomatic Rectal Chlamydia in Men – Physician’s Weekly

 

Commentary on Twitter

 

Perspective | Are Chinese COVID vaccines underperforming? a dearth of real-life studies leaves unanswered questions.

25 Jun, 2021 | 10:26h | UTC

Are Chinese COVID Vaccines Underperforming? A Dearth of Real-Life Studies Leaves Unanswered Questions – Health Policy Watch

Related: WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.

 

CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges.

25 Jun, 2021 | 10:13h | UTC

CDC advisory panel backs use of dengue vaccine in high-risk areas, despite delivery challenges – STAT

 

Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients can improve the immunogenicity of the vaccine.

24 Jun, 2021 | 10:32h | UTC

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients – New England Journal of Medicine

 

Another study shows a single dose of an mRNA vaccine has maximal effects in those with past infection.

24 Jun, 2021 | 10:38h | UTC

Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses – ACS Nano

Related: France recommends single dose of vaccine if previous Covid infection detected. AND [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19

 

Commentary on Twitter

 

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

24 Jun, 2021 | 09:52h | UTC

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – New England Journal of Medicine

Related: Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose AND Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

 

Report: SARS-CoV-2 variants and vaccines.

24 Jun, 2021 | 10:33h | UTC

SARS-CoV-2 Variants and Vaccines – New England Journal of Medicine

 

Analysis | Future of covid-19 vaccine pricing: lessons from influenza – “Routine use of covid-19 vaccines could strain health budgets if pricing follows the pattern seen with influenza vaccines”.

24 Jun, 2021 | 09:50h | UTC

Future of covid-19 vaccine pricing: lessons from influenza – The BMJ

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.